Skip to content
Menu

MediWound Ltd. MDWD

Full chart Compare
Set alert

Price alert · MDWD

All alert types
13.54 USD -0.07 (-0.51%)

Regular-session close

13.54 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

13.35 Day range 13.67
11.80 52-week range 19.70
YTD
-26.65%
1 year
-24.19%

5D -0.43 (-3.08%)

1314TueWedThuFriMon13.55
Market cap
194.84M
Revenue (ttm)
20.14M
Profit margin
-99.17%
EPS (ttm)
-2.59
Shares out
10.79M
Forward P/E
-7.96
YTD return
-26.65%
1-year return
-24.19%
Volume
171.65K
Avg volume
122.71K
Open
13.36
Previous close
13.61
Day's range
13.35 – 13.67
52-week range
11.80 – 19.70
Beta
0.84
Price target
29.00 (+114.2%)

Key statistics

50-day average
17.27
200-day average
17.21
Enterprise value
138.07M
Price / sales
9.47
Price / book
5.16
Revenue growth
6.10%
Free cash flow
-8.42M
Total cash
29.21M
Total debt
6.36M
Return on equity
-75.66%
Short % of float
6.43%

Fundamental scorecard

3 of 25 checks passed on MDWD’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
MDWD Revenue — quarterly 3.57M
MDWD Net income — quarterly -5.99M
MDWD EPS — quarterly -0.46

Earnings

MDWD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 26, 2024Sep 1, 2024-0.48-0.98-0.50-104.17%
Aug 14, 2024Jun 1, 2024-0.42-0.68-0.26-61.90%
May 29, 2024Mar 1, 2024-0.40-0.39+0.01+2.50%
Mar 21, 2024Dec 1, 2023-0.23-0.19+0.04+17.39%
Nov 21, 2023Sep 1, 2023-0.45-0.24+0.21+46.67%
Aug 15, 2023Jun 1, 2023-0.410.10+0.51+124.39%

Upgrades / downgrades

MDWD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 27, 2024HC Wainwright & Co.mainBuyBuy
Oct 11, 2024HC Wainwright & Co.reitBuyBuy
Aug 15, 2024HC Wainwright & Co.reitBuyBuy
Jul 16, 2024HC Wainwright & Co.reitBuyBuy
May 30, 2024HC Wainwright & Co.reitBuyBuy
Mar 22, 2024HC Wainwright & Co.reitBuyBuy

About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel

News

Your note

Sign in to keep a note on MDWD — it syncs with the Stock Master app.

Institution ownership

MDWD institution ownership
Holder% heldSharesValueReported
Investor AB6.83%872,09315.41MSep 29, 2024
Yelin Lapidot Holdings Management Ltd.5.88%750,74313.27MSep 29, 2024
Rosalind Advisors, Inc.4.92%628,05011.10MSep 29, 2024
Blackrock Inc.3.39%432,9967.65MSep 29, 2024
Balyasny Asset Management LLC1.30%165,7362.93MSep 29, 2024
Sargent Investment Group, LLC0.92%117,1922.07MSep 29, 2024

Fund ownership

MDWD fund ownership
Holder% heldSharesValueReported
iShares Russell 2000 ETF1.62%206,3803.65MOct 30, 2024
ARK ETF Tr-ARK Israel Innovative Technology ETF0.91%115,7652.05MOct 30, 2024
Fidelity Small Cap Index Fund0.64%81,7441.44MAug 30, 2024
iShares Russell 2000 Growth ETF0.55%70,1501.24MOct 30, 2024
Vanguard Russell 2000 Index Fund0.25%32,376572.08KAug 30, 2024
1290 Fds-1290 Essex Small Cap Growth Fd0.17%21,233375.19KJul 30, 2024